Please login to the form below

Not currently logged in
Email:
Password:

trastuzumab emtansine

This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations

The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that

Latest news

More from news
Approximately 5 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics